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Dietary arginine supplementation attenuates renal damage af-
ter relief of unilateral ureteral obstruction in rats.
Background. Progression of renal injury after relief of unilat-
eral ureteral obstruction (UUO) has been demonstrated. Nitric
oxide (NO) may be an effective intervention due to its vasodila-
tory, antifibrotic, and anti-apoptotic effects. Herein, we used
dietary L-arginine (ARG) supplementation in a UUO relief
model.
Methods. This study comprised group 1, control (no treat-
ment). All other rats were subject to 3-day UUO, which was then
relieved, and the rats maintained for 7 additional days. Group 2,
no additional treatment; group 3, L-ARG; group 4, L-NAME,
NO synthase inhibitor; group 5, ARG and L-NAME. Urinary
NO2/3 was quantified. GFR and ERPF were measured at day 10.
Interstitial fibrosis and fibroblast expression, macrophage infil-
tration, tubular apoptosis, and proliferation, NOS expression,
and the levels of tissue TGF-b were evaluated.
Results. Urinary NO2/3 was significantly increased by ARG
treatment and decreased by L-NAME. GFR and ERPF mea-
sured 7 days following relief were not significantly different in
the previously obstructed kidneys (POK) of groups 2 and 3.
L-NAME significantly reduced GFR and ERPF in the POK.
ARG significantly reduced apoptosis, macrophage infiltration,
and fibroblast expression in the POK. L-NAME exacerbated
the effects on apoptosis and fibroblasts. Fibrosis was minimal in
groups 1 through 3, but was significantly increased by L-NAME.
ARG did not affect renal NOS expression and tissue TGF-b1
levels.
Conclusion. Dietary ARG supplementation during UUO re-
lief did not improve ERPF or GFR. However, renal damage,
including fibrosis, apoptosis, and macrophage infiltration was
significantly improved by ARG treatment. This suggests that
increasing NO availability could be beneficial in the setting of
UUO relief.
1See Editorial by Frøkiær, p. 894
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Unilateral ureteral obstruction (UUO) is a common
clinical finding [1]. Prominent changes in UUO include
decreases in renal function, and increased fibrosis, tubu-
lar apoptosis, and cellular proliferation. After UUO, both
renal blood flow (RBF) and glomerular filtration rate
(GFR) decrease, and the decreases are permanent with-
out intervention. If UUO is relieved within a certain
period, both RBF and GFR increase. However, the re-
coverability of renal function in the previously obstructed
kidney (POK) depends on the duration of UUO and the
species being examined [2–5].
Studies have also examined the effects of relief of UUO
on the histopathologic changes that accompany UUO.
Continuous progression of renal injuries, including inter-
stitial fibrosis and tubular apoptosis, has been found in
the POK of neonatal and adult rats after relief of UUO
[6–8]. Thus, relief of UUO by itself may not be sufficient
to improve the function and histopathology of the kid-
ney, but may require a concurrent pharmacologic inter-
vention. Effective intervention may minimize irreversible
renal injury.
Previous studies in UUO models have shown a pro-
tective effect of NO on renal function [9–12], interstitial
fibrosis [13, 14], and renal tubular apoptosis [15]. Thus,
augmentation of NO may improve RBF and GFR, and
renal injury in the POK. In the present study, we used
dietary L-arginine supplementation to increase NO pro-
duction, an approach that has been shown previously by
our group and others [16–18]. We used a 3-day period of
UUO, after which the obstruction was relieved and the
rats followed for a further 7 days. Animals received either
no other treatment, or were treated with L-arginine, the
NOS inhibitor L-NAME, or L-arginine and L-NAME. At
the end of 10 days, we assessed the effect of increased NO
on both renal function and renal damage.
METHODS
Experimental protocol
Five groups were studied (Table 1). Renal function of
rats (male Sprague-Dawley; 300 to 400 g) without UUO
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Table 1. Percent kidney weight 7 days following relief of UUO
Right kidney Left kidney
(contralateral) (previously obstructed)
Group # (N) Treatment (% BW) (% BW)
1 (8) Untreated control 0.36 ± 0.01a
2 (8) 3-day UUO + 7-day relief 0.50 ± 0.02b 0.52 ± 0.03b
3 (7) 3-day UUO + 7-day relief + arginine 0.46 ± 0.02b 0.45 ± 0.02b
4 (6) 3-day UUO + 7-day relief + L-NAME 0.48 ± 0.03b 0.47 ± 0.02b
5 (6) 3-day UUO + 7-day relief + arginine + L-NAME 0.49 ± 0.03b 0.46 ± 0.02b
aKidney weight, control right kidney in group 1.
bP < 0.05, compared to control kidney.
was measured as control (group 1, N = 8). Animals in
groups 2 through 5 were subject to left UO, and obstruc-
tion was relieved after 3 days of UUO, as described be-
low. In all relieved groups, GFR and ERPF in both kid-
neys were measured 7 days after relief. Group 2 (N = 8)
rats had no further treatment. Rats in group 3 (N = 7)
were treated with 1% L-arginine in their drinking water
for 25 days (starting 15 days prior to UUO and contin-
uing through 3 days of UUO and 7 days of relief), at
which time renal function was measured. Rats in group
4 (N = 6) were treated with NOS inhibitor, N-nitro-L-
arginine methyl ester (L-NAME) for 12 days (daily in-
traperitoneally injection, starting 2 days prior to UUO
and continuing through 3 days of UUO and 7 days of re-
lief), at which time renal function was measured. Group
5 (N = 6) was treated with L-arginine and L-NAME
(as above), and then renal function was measured. All
protocols were approved by the institutional animal care
committee.
In vivo relief of UUO (ureteroneocystotomy)
Ureteral obstruction was carried out by ligating the left
ureter at the end of lower ureter, just above the uretero-
vesical junction [19]. Three-day UUO was reversed using
microsurgical methods previously described [19]. Briefly,
rats were anesthetized intraperitoneally, and positioned
supine under 2 heating lamps. A midline abdominal
incision was made, and under 8× magnification, the di-
lated left ureter was identified and dissected free of
surrounding tissues. An 18-gauge angiocatheter was in-
troduced through the mid-anterior bladder wall, and ex-
ited through the left lateral bladder wall. The ureter was
transected approximately 1 cm above the level of ob-
struction, and the open end was cannulated with the an-
giocatheter. Using 10–0 nylon suture, a ureteral-bladder
anastomosis was effected in an interrupted fashion. The
catheter was then removed, and the bladder-puncture de-
fect was repaired with a 7–0 prolene suture. The abdom-
inal incision was closed in 2 layers, including muscle and
skin.
Renal function measurement
Renal function was measured as previously described
[16]. A 24 g × 19 mm angiocatheter was secured in
the right jugular vein. A bolus of lactated Ringer’s
(LR) solution was slowly injected intravenously in the
amount of 1% body weight (BW), and bolus of 1% para-
aminohippurate (PAH) and 1.5% inulin in LR was in-
jected in the amount of 0.2% BW. A solution of 1% PAH
and 1.5% inulin in LR was infused at 10 L/min/100g BW,
and was maintained for at least 60 minutes. A midline ab-
dominal incision was made, followed by a small transverse
incision in the ureter. PE10 tubing was inserted into the
right and left ureters of control rats, whereas PE50 tubing
was inserted into the left ureter of the obstructed kidney
due to its dilatation. Ten minutes after catheter insertion,
urine collections were started. Twenty-minute urine col-
lections were made from each kidney 3 times, and 450 lL
of arterial blood was collected at the midpoint of each
collection. This volume was replaced by the infusions so
the rat was not volume depleted. After measurement of
renal function, both kidneys were harvested for analy-
sis. Following renal function measurements, a tube was
inserted into the middle ureter, and was ligated with 3–0
silk. Saline solution (0.9%) was introduced into the ureter
from a level of approximately 18 inches using gravity,
and the patency of the anastomosis was confirmed. Then,
both kidneys were harvested for histologic and protein
analyses.
Kidney weight
At harvest, each kidney was decapsulated, washed
with saline, bisected coronally, blotted dry on gauze, and
weighed. The whole kidney weight was expressed as a
percentage of BW determined at the time rats were eu-
thanized.
Determination of ERPF (using para-aminohippurate)
and GFR (using inulin)
Urine and plasma concentrations of para-
aminohippurate and inulin were detected using standard
chemical methods as previously described [16, 19].
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Para-aminohippurate was detected colorimetrically at
550 nm and inulin at 595 nm. Clearances were calcu-
lated using standard formulas. For each rat, the values
obtained for 3 clearance periods were averaged. Values
were normalized to BW.
Urinary NO2/3 and cyclic GMP
To assess the effects of arginine and L-NAME, a 24-
hour urine sample was collected in metabolic cages 1
day prior to UUO in groups 2 through 5. Twenty-four–
hour urine was collected in a reservoir containing 2-
propanol and samples were frozen at −80◦C until as-
say. Urinary NO2/3 levels were measured by the Griess
reaction after copperized cadmium treatment, as previ-
ously described [16]. Urinary cyclic GMP was measured
by enzyme-linked immunosorbent assay (ELISA) (As-
say Designs, Inc., Ann Arbor, MI, USA). The results were
normalized to BW.
Determination of tissue TGF-b1 level
Samples of frozen tissue were assayed for TGF-b1
using ELISA as previously described (20; Quantikine;
R&D Systems, Minneapolis, MN, USA). Analysis was
completed using dual wavelength readings. Standard
curve and all samples were run in duplicate.
Assessment of renal morphology and interstitial fibrosis
After renal function measurement, kidney sections
were fixed in 10% neutral buffered formalin and embed-
ded in paraffin. Five-micrometer sections were stained
with Masson’s trichrome, and were examined by a board-
certified pathologist (S.V.S.) in a blinded fashion. Prox-
imal tubules were identified by their plump lining cells
containing eosinophilic granular cytoplasm and promi-
nent luminal brush borders. Distal tubules are lined
with low cuboidal cells containing clear to amphophilic
cytoplasm and central nuclei with absence of brush
borders. The distinction between distal tubules and col-
lecting ducts was made on the basis of location in the
renal parenchyma, and the size and frequency of occur-
rence in that location. In the outer and inner medulla,
which are depicted in most of the figures, segments of the
distal tubules are much narrower than collecting ducts.
The presence of interstitial fibrosis was assessed in slides
stained with Masson’s trichrome and validated by mea-
surements of interstitial volume, using a point-counting
method as previously described [21].
Immunochemical analysis
Immunohistochemical analyses for iNOS, eNOS,
macrophage, and PCNA were performed as previously
described [15, 16]. Macrophages and renal tubules (for
PCNA) were counted in 10 high-power fields (×400) by
2 different independent investigators in a blinded fashion.
To quantitate apoptotic cells, the TUNEL assay was per-
formed as previously described [15, 20]. TUNEL-positive
renal tubules were quantitated as above. We also ana-
lyzed tissue for the presence of fibroblasts using immuno-
histochemistry. The antibody utilized was Dako # S100-
A4 (Dako Corp., Carpinteria, CA, USA). The S100-A4
antigen is also known as FSP-1, and has been found to
be expressed by fibroblasts, but not epithelial cells [22,
23]. Antigen was retrieved by incubating cells with pro-
teinase K for 20 minutes in an oven. Slides were then
processed as is carried out routinely for immunoperox-
idase. The primary antibody was used at a dilution of
1:100. Ten high-power fields were counted in each slide
and averaged together. Staining for S100-A4 was found in
spindle-shaped interstitial cells, and also in cells that were
round, and were identified as inflammatory cells by the
pathologist. Only spindle-shaped cells were included in
the counts. Samples incubated without primary antibody
exhibited no staining.
Western blotting analysis
Western blot analyses for iNOS and eNOS were per-
formed using standard techniques as previously described
[15, 16]. iNOS and eNOS were detected at 130 kb and 133
kb, respectively. Relative intensity was expressed as per-
cent control intensity. Five samples were analyzed per
group.
Statistical analysis
All results are expressed as the mean ± SE, and were
analyzed for significance by the one-way analysis of vari-
ance (ANOVA) and multiple comparison tests.
RESULTS
Kidney weight
Kidney weights were measured at the time of euthana-
sia (Table 1). The relative kidney weight in normal kidney
was 0.36 ± 0.01% BW. In all other groups, both kidney
weights were significantly higher than normal kidney (P <
0.05). Kidney weights were not significantly different be-
tween POK and contralateral kidney (CK) in any groups.
The effect of L-arginine and L-NAME on urinary NO2/3
and cyclic GMP
To verify the effect of L-arginine and L-NAME treat-
ment on NO production, urinary NO2/3, and cyclic GMP
were measured 1 day prior to UUO. Urinary NO2/3
was significantly higher in arginine-treated rats (group
3, 2053 ± 172 nmol/24hr/100g) than group 2 (1111 ±
107 nmol/24hr/100g; Fig. 1A), confirming increased NO
production. L-NAME treatment significantly blunted the
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Fig. 1. The effect of L-arginine and L-NAME treatment on urinary NO2/3 and cyclic GMP. A 24-hour urine specimen was collected one day prior
to UUO, and NO2/3 and cGMP measured as in Methods. (A) Urinary NO2/3 was significantly higher in the arginine-treated group 3 as compared
to control group 2, and this was blunted by L-NAME (group 4). (B) Urinary cGMP was significantly higher in the arginine-treated group 3 as
compared to control group 2, and this was blunted by L-NAME (group 4). ∗P < 0.05, compared to group 2. ∞P < 0.05 compared to indicated group.
Table 2. GFR in normal rats and rats which underwent relief of UUO
GFR (CK) GFR (POK) a Total GFR %GFR (POK)
mL/min/100g mL/min/100g mL/min/100g %
Group 1 0.30 ± 0.02 0.31 ± 0.02 0.61 ± 0.04 50.3 ± 1.50
Group 2 0.43 ± 0.04b 0.24 ± 0.03 0.67 ± 0.06 36.1 ± 3.0b
Group 3 0.39 ± 0.05 0.26 ± 0.03 0.64 ± 0.07 40.2 ± 1.9b
Group 4 0.33 ± 0.11 0.11 ± 0.01b,c 0.44 ± 0.03b,c 25.5 ± 3.1b,c
Group 5 0.29 ± 0.03c 0.11 ± 0.03b,c 0.40 ± 0.06b,c 25.5 ± 4.0b
aUUO and relief were performed in the left kidney in groups 2 through 5.
bP < 0.05, compared to group 1.
cP < 0.05, compared to groups 2 and 3.
effect of L-arginine in group 5 compared with group 3.
Urinary NO2/3 in group 4 was significantly lower than
group 2 (P < 0.05).
Urinary cGMP was significantly higher in arginine-
treated rats (Fig. 1B) than control, which validates the
result of urinary NO2/3. L-NAME treatment blunted
the effect of L-arginine in group 5 compared with
group 3.
Renal function after relief of UUO
In group 1, GFR was 0.30 ± 0.02 mL/min/100g in the
right kidney (Table 2), with no significant differences
between left and right kidneys. In groups 2 through 5,
GFRs were significantly different between POK and CK
(P < 0.05). In the POK, GFRs in groups 2 (0.24 ± 0.03
mL/min/100g) and 3 (0.26 ± 0.03 mL/min/100g) were not
significantly different from group 1. In contrast, GFRs
in the POK of groups 4 and 5 were significantly lower
than group 1. L-NAME treatment significantly decreased
GFRs in groups 4 and 5 compared to groups 2 and 3. In
CK, GFR in group 2 was significantly higher than group
1. GFR of CK in groups 3 through 5 was not significantly
different from group 1.
We also examined total GFR as the sum of the GFRs
in both left and right kidneys (Table 2). Total GFR in
groups 2 and 3 was not significantly different from that
in group 1. L-NAME treatment significantly decreased
total GFR in groups 4 and 5. We calculated the percent
GFR in the POK. In groups 2 through 5, the percent
GFR in POK was significantly lower than group 1 (50.33
± 1.51% of total). Percent GFR in the arginine-treated
group was not significantly different from group 2. L-
NAME treatment, with or without concomitant arginine
treatment, significantly decreased total GFR compared
to groups 2 and 3 (P < 0.05).
In group 1, ERPF was 1.02 ± 0.11 mL/min/100g in the
right kidney and 1.01 ± 0.14 mL/min/100g in the left kid-
ney (Fig. 2). In groups 2 and 3, ERPF in POK was not sig-
nificantly different from group 1. In contrast, L-NAME
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Fig. 2. The effect of L-arginine on the recoverability of ERPF follow-
ing the relief of 3-day UUO. ERPF was measured in both POK and CK
in all groups by PAH clearance as in Methods. ERPF was not signif-
icantly different in groups 2 and 3, but was significantly decreased by
L-NAME treatment (groups 4 and 5). ∗ P < 0.05, compared to group
1, ∞ P < 0.05, compared to group 2, † P < 0.05, compared to group 3.
treatment decreased ERPF in both kidneys in groups 4
and 5 compared to group 1.
Renal morphology and interstitial fibrosis
Interstitial fibrosis and renal morphology were as-
sessed by examination of Masson’s trichrome slides. Mild
dilatation of distal and collecting tubules was seen in all
POK. Inflammation (leukocytes infiltration), mainly in
peripelvic area, was also noted. In L-NAME–treated rats,
damaged tubules surrounded by interstitial fibrosis were
seen in some cortical area. CKs in all groups had no re-
markable change in their architectures or evidence of in-
flammation. In CK, there was no significant fibrosis in any
group. In POK, mild blue staining was seen in some ani-
mals in group 2 (Fig. 3A), and less blue staining was seen
in group 3 (Fig. 3B). Significantly increased blue staining
was seen in group 4 compared to group 2 (Fig. 3C) and
group 5 (not shown). We evaluated blue-stained collagen
deposition. In the POK, mild blue staining was seen in
some animals in group 2 (4.80 ± 1.21%, Fig. 4A), and
less blue staining was seen in group 3 (2.42 ± 1.21%,
Fig. 4B). Increased blue staining was seen in group 4
(12.88 ± 2.93%, P < 0.05, compared to group 2, Fig. 5C)
and group 5 (6.45 ± 1.68%).
In situ TUNEL
POK in groups 2 through 5 showed significantly higher
tubular apoptosis than control normal kidneys (0.93 ±
0.16 nuclei per high-power field; nuclei/HPF; Fig. 4A).
TUNEL+ cells were localized to dilated distal and
collecting tubules. Arginine treatment significantly
lowered apoptosis in the POK in group 3 (Fig. 4C)
Fig. 3. Trichrome staining of POK. Interstitial fibrosis was visualized
by Masson’s trichrome staining, and interstitial volume determined by
a point counting method (see text for numbers). Mild dilatation of col-
lecting ducts and distal tubules was seen in all released groups. Renal
medulla is shown for all groups. (A) In POK, mild blue staining was seen
in some animals in group 2. (B) Less blue staining was seen in group
3 (arginine treatment). (C) Increased blue staining was seen in group
4 (L-NAME treatment). Abbreviations (this and all following figures):
DT, distal tubule; CD, collecting duct.
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Fig. 4. Apoptosis in kidney following relief of UUO. Apoptosis was measured by the TUNEL assay as in Methods. (A) Graphic representation of
apoptosis in all groups demonstrating decreases in apoptosis following arginine treatment (group 3) and increases following L-NAME treatment
(group 4). Renal medulla is shown for all groups. (B–D) In situ TUNEL. (B) POK, group 2; (C) POK, group 3; (D) POK, group 4. ∗P < 0.05
compared to group 1; ∞P < 0.05 compared to corresponding CLK. # P < 0.05 compared to POK of group 2.
compared to group 2 (Fig. 4B). L-NAME treatment alone
(Fig. 4D) resulted in significantly more apoptosis (17.8 ±
3.7 cells/HPF) than all other groups, and blunted the ef-
fect of L-arginine when both were administered together.
Apoptosis in POKs in groups 2 through 5 was significantly
higher than in their CKs (P < 0.05), and there was no sig-
nificant difference among CKs, which were not different
from control.
Tissue TGF-b1 level
Tissue TGF-b1 levels in POK of groups 2 through 5
were all significantly higher than group 1 (Fig. 5). Tissue
TGF-b1 levels in CK of groups 2 through 4 were signifi-
cantly higher than control kidney. Although TGF-b1 lev-
els tended to be higher in POK, there was no significant
difference between POK and CK in all groups. Neither
L-arginine nor L-NAME affected TGF-b1 in the POK or
CLK.
Macrophage infiltration in the kidney
In groups 2 through 5, the numbers of macrophages
in the POK were significantly higher than in control kid-
ney (Fig. 6A, P < 0.05). In the POK, arginine treatment
(9.22 ± 0.56 macrophages/HPF, Fig. 6C) significantly
reduced the number of macrophages compared to
group 2 (27.43 ± 4.01 macrophages/HPF, Fig. 6B; P <
0.05). L-NAME treatment had no significant effect on
macrophage infiltration compared to group 2 (32.75 ±
2.42 macrophages/HPF, Fig. 6D), and did not blunt the
effect of L-arginine alone.
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Fig. 5. The concentration of TGF-b1 in kidney tissues. Tissue TGF-b1
was measured as described in Methods. Tissue TGF-b1 levels in POK
of groups 2 through 5 were all significantly higher than control. ∗P <
0.05 compared to group 1.
Fibroblast expression in the kidney
There was a small number of interstitial fibroblasts
present in control kidneys (5.4 ± 0.2/HPF; Fig. 7A and B).
All POK in groups 2 through 5 had significantly higher
fibroblast expression compared to group 1. L-arginine
caused a small but significant decrease in fibroblast ex-
pression in group 3 (Fig. 7D; 13.6 ± 0.9 FSP+ cells/HPF
vs. 17.6 ± 0.8 FSP+ cells/HPF) compared to group 2
(Fig. 7C). In contrast, L-NAME treatment alone signif-
icantly increased fibroblast expression (Fig. 7A and E),
and was able to reverse the effect of L-arginine. CLK fi-
broblast expression was significantly lower than POK ex-
pression in all groups, and was not significantly different
from control.
Detection of PCNA expression
To determine the effect of L-arginine on renal tubu-
lar proliferation after relief of UUO, immunostaining of
PCNA was performed (Fig. 8A). Both POK and CK in
groups 2 and 4, and POK in group 5, showed signifi-
cantly higher tubular proliferation than group 1 (P < 0.05;
Fig. 8B). L-arginine treatment significantly reduced the
numbers of PCNA-positive cells in both kidneys (4.70 ±
0.36 cells/HPF in CK and 6.25 ± 1.07 cells/HPF in POK;
Fig. 8C) when compared to group 2 (10.52 ± 0.83 posi-
tive cells/HPF in CK and 15.53 ± 1.98 cells/HPF in POK;
P < 0.05). L-NAME alone did not affect the number of
PCNA-positive cells when compared to group 2.
Immunostaining of iNOS and eNOS
To evaluate the effect of L-arginine on the expression of
iNOS and eNOS, and to determine their localization, im-
munostaining for iNOS and eNOS was performed. iNOS
was weakly expressed in renal tubular cells in control nor-
mal kidney. Relatively higher staining was seen in cortex
(not shown). In POK, clear staining was seen in proximal
tubules and distal tubules (Fig. 9A). Glomeruli had weak
staining. Tubular cells in medulla were also stained. In
CK, staining similar to that seen in the POK was noted
(not shown). In the arginine-treated group (Fig. 9B), no
significant difference in localization or expression was
seen compared to group 2. eNOS staining was also per-
formed. In control kidney, eNOS was weakly expressed
in tubular cells in both cortex and medulla (not shown).
In POK, clear staining was seen in proximal tubules and
distal tubules (Fig. 9C). Slightly less staining was seen
in collecting duct. Glomeruli had some staining. In CK,
staining was also seen in the same location. As with iNOS,
no significant difference was found between groups 2 and
3 (Fig. 9D).
Western analysis for iNOS and eNOS
To confirm the immunohistochemical results, Western
blot analyses were performed in groups 2 and 3. Intensity
was expressed as an arbitrary unit, with CK of group 2 set
arbitrarily at 100%; comparisons are shown in Table 3.
Representative Western blots are shown in Figure 10.
iNOS expression (Fig. 10A) was not different between
CK and POK in groups 2 and 3. There was no significant
difference in iNOS expression between groups 2 and 3 in
both CK and POK. Similarly, eNOS expression (Fig. 10B)
was not different between CK and POK in both groups.
There was no significant difference in eNOS expression
between groups 2 and 3 in both kidneys. These results sug-
gested that L-arginine treatment did not affect the levels
of NOS expression.
DISCUSSION
The obstructed kidney is characterized by progressive
renal fibrosis and damage, and a decline in both renal
blood flow (RBF) and GFR. Relief of obstruction is char-
acterized by a variable recovery in renal function, with
less known about changes in renal damage. In the present
experiments, we relieved a 3-day UUO and examined rats
at 7 days. When L-arginine was present during the recov-
ery phase, there was a diminution in the many of the
markers of renal damage, without effects on renal func-
tion. In contrast, in the presence of the NOS inhibitor,
L-NAME, there were severe decreases in renal function,
as well as increases in renal damage. These results suggest
that NO is important in maintaining renal function fol-
lowing relief of UUO, and that providing additional NOS
substrate may be beneficial for improving renal damage
in the post-relief period.
The recovery of the kidney after relief of UUO has
been studied by several investigators [3–6]. In most cases,
the studies have involved an examination of either renal
function or renal damage, but not both. However, since
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Fig. 6. Macrophage infiltration in kidney following relief of UUO. Macrophages were localized immunohistochemically as in Methods. (A) Graphic
representation of macrophage infiltration in all groups demonstrating decreases in macrophages following arginine treatment (group 3), which was
blunted by L-NAME treatment (group 5). Renal cortex is shown for all groups. (B–D) Immunohistochemistry. (B) POK, group 2; (C) POK, group
3; (D) POK, group 4. ∗P < 0.05 compared to group 1; # P < 0.05 compared to POK of group 2.
several studies have demonstrated that GFR can be cor-
related with interstitial fibrosis [24, 25], it is important to
examine not only how relief of UUO affects GFR and
RBF, but also if interstitial fibrosis and other markers of
renal damage progress. Previous studies from our labo-
ratory [19] demonstrated that, after relief of 3-day UUO,
recovery of renal function is complete by 14 days after re-
lief, whereas renal damage progressed through 28 days of
recovery. These results are similar to those of Chevalier et
al in a neonatal rat model. At 28 days after relief of UUO,
interstitial collagen, a-smooth muscle actin, and TGF-
b1 were dramatically increased in the POK compared to
sham-operated rats [6]. After 28 days of relief, GFR in the
POK was not significantly different from baseline GFR.
At 1 year, however, following relief of UUO, interstitial
collagen, macrophage infiltration, and a-smooth muscle
actin immunostaining were significantly increased in both
POK and CLK, and GFR in the POK was at a level of only
20% of sham-operated rats [7]. Thus, relief of UUO may
provide protection of renal function in the short term,
but the fibrotic mechanisms set in motion by obstruction
appear to lead to eventual long-term renal dysfunction.
NO has been shown to be protective in both acute and
chronic UUO models, with effects on both renal function
and renal damage. Although L-arginine has not previ-
ously been used during the relief of UUO, its restora-
tive effect on renal function have been reported in acute
UUO [10, 11]. In addition, the NO donor, SNAP, also
attenuated renal blood flow in a 24-hour UUO model
[9]. Gene therapy with iNOS has also been shown to be
Ito et al: Dietary L-arginine attenuates renal damage in UUO 523
30
25
20
15
10
5
0
FS
P+
 
ce
lls
/H
PF
CK
OK
Gr
ou
p 1
Gr
ou
p 2
Gr
ou
p 3
Gr
ou
p 4
Gr
ou
p 5
*
*
*
*
#
A
Fig. 7. Fibroblast expression in kidney following relief of UUO. Fibroblasts were localized immunohistochemically using the S100A4 antibody as
described in Methods. (A) Graphic representation of fibroblast expression in all groups demonstrating decreases in fibroblasts following arginine
treatment (group 3) and increases following L-NAME treatment (group 4). (B–E) Immunohistochemistry. Renal medulla is shown for all groups.
(B) Control kidney, group 1; (C) POK, group 2; (D) POK, group 3; (E) POK, group 4. ∗P < 0.05 compared to group 1 and to corresponding CLK;
#P < 0.05 compared to POK of groups 2, 4, and 5.
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Fig. 8. PCNA expression in kidney following relief of UUO. PCNA
was localized immunohistochemically as described in Methods. (A)
Graphic representation of PCNA expression in all groups demonstrat-
ing decreases in PCNA expression following arginine treatment (group
3), and which was blunted by L-NAME treatment (group 5). (B and
C) Immunohistochemistry. Renal medulla is shown. (B) POK, group 2;
(C) POK, group 3. NS, not statistically significant. ∗P < 0.05, compared
to group 1; #P < 0.05, compared to group 2.
beneficial in acute UUO [12]. In experiments examining
relief of 1-, 2-, and 3-week UUO in rats, an angiotensin-
converting enzyme (ACE) inhibitor showed a restorative
effect on renal function [4]. Although not measured (or
even known about) in that study, NO production has been
shown to be augmented by use of an ACE inhibitor in a
5-day UUO model [13]. Thus, the restorative effect of the
ACE inhibitor in the relief experiments cited above may
be in part due to NO production. NO has also been shown
to be protective against renal damage in UUO, with both
antifibrotic and anti-apoptotic effects. Morrissey et al [13]
demonstrated that L-arginine treatment significantly de-
creased interstitial fibrosis. In our previous studies using
iNOS knockout mice, we found both interstitial fibrosis
and apoptosis were increased. In vitro studies examining
stretch-induced apoptosis in renal epithelial cells demon-
strated a protective effect of L-arginine or SNAP, and en-
hanced apoptosis with NOS inhibitors [15, 26].
In the present experiments, we used L-ARG, L-
NAME, or L-ARG + L-NAME in a model of relief of
3-day UUO. Measurement of urinary NO metabolites
demonstrated that ARG alone increased urinary NO.
When L-NAME was given, there was a significant de-
crease in NO that was not completely reversed by con-
comitant administration of L-ARG. Although ERPF and
GFR were lower in group 2 than group 1, they were not
statistically significantly different; therefore, it was diffi-
cult to discern an effect of L-ARG alone. Nevertheless,
there was a striking effect of L-NAME, which severely
decreased both ERPF and GFR. These results suggest
that NO is involved in maintaining ERPF and GFR dur-
ing the 7-day recovery period. Providing substrate, along
with L-NAME, was not able to reverse the effects of the
NOS inhibitor. It is possible that there was insufficient
L-ARG provided to compete with L-NAME, or that the
L-ARG was not accessible to sites at which it could be
metabolized to NO, and additionally, to improve renal
function.
Renal damage in UUO is characterized by interstitial
fibrotic changes, tubular apoptosis, and cellular changes,
including macrophage infiltration and the presence of in-
terstitial fibroblasts. We examined the effect of arginine
and L-NAME treatment on each of these parameters
compared to relief of UUO with no other treatment. In
the present study, minimal fibrosis was seen in rats in
which a 3-day UUO was relieved, and the rats followed
for an additional 7 days. Therefore, it would be difficult
to note an improvement with L-arginine treatment. How-
ever, the blocking of NO production by L-NAME signif-
icantly increased interstitial fibrosis in this model. These
results are in agreement with Morrissey et al [13], who
demonstrated that L-arginine treatment significantly de-
creased interstitial fibrosis in UUO, and who showed that
L-NAME blocked the beneficial effects of an ACE in-
hibitor by decreasing NO synthesis.
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Fig. 9. Immunohistochemical localization of iNOS and eNOS in kidney following relief of UUO. iNOS and eNOS were localized as described in
Methods. (A) iNOS staining in POK, group 2. (B) iNOS staining in POK, group 3. (C) eNOS staining in POK, group 2. (D) eNOS staining in POK,
group 3.
In the control 7-day relieved POK, there was a signifi-
cant increase in apoptotic tubular cells. This increase was
attenuated with arginine treatment, and exacerbated with
L-NAME treatment, which also blunted the effect of L-
arginine. Although both proapoptotic and anti-apoptotic
effects of NO have been demonstrated [27], these results
demonstrate that NO is anti-apoptotic, not only during
obstruction, but during relief, as well. The specific target
of NO in this model has not been determined, but some
involvement of caspase-3 in epithelial tubular cell apop-
tosis has been demonstrated [28].
In addition, macrophage infiltration, one of the mark-
ers of interstitial damage, was significantly decreased
by L-arginine in this study. A similar result was previ-
ously seen when L-arginine was used in UUO [13] and
a bilateral UO model [27]. NO may decrease the num-
ber of macrophages in the kidney through direct effects
on apoptosis, or through effects on macrophage recruit-
ment. Thus, NO has been shown to cause apoptosis in
macrophages [30]. Furthermore, NO has also been shown
to regulate RANTES, a protein involved in the recruit-
ment of macrophages. In wound healing, it has been
shown that NO down-regulates expression of RANTES
in keratinocytes, leading to decreased macrophage in-
filtration [32]. In an animal model of endotoxemia,
arginine administration decreased glomerular RANTES
and, conversely, L-NAME increased both RANTES and
glomerular macrophage infiltration [32]. Surprisingly, L-
NAME treatment alone did not increase the number of
macrophages in the kidney, perhaps suggesting differ-
ences in localization of arginine and L-NAME, which
could influence their effect on macrophage infiltration.
The number of spindle-shaped cells expressing S100A4
increased in the relieved POK. It is known that FSP-1 is
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Table 3. Western blot for iNOS and eNOS in control group and arginine-treated group
Group 2–CK Group 2–POK Group 3–CK Group 3–POK
iNOS expression 8795 ± 1347 8995 ± 1286 8357 ± 1020 8778 ± 1280
(100%) (102.3 ± 14.6%) (95.0 ± 11.6%) (99.8 ± 14.6%)
eNOS expression 10,093 ± 1155 9862 ± 1572 9625 ± 872 9745 ± 867
(100%) (97.7 ± 15.6%) (95.4 ± 8.6%) (96.6 ± 8.6%)
All percentages were expressed as% of control.
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Fig. 10. Western blot analysis for NOS in
groups 2 and 3. Western blots for iNOS (A)
and eNOS (B) were carried out as in Meth-
ods. iNOS expression was not different be-
tween CK and POK in both groups 2 and 3.
Similarly, eNOS expression was not different
between CK and POK in both groups.
expressed in interstitial fibroblasts, and that FSP is identi-
cal to S100-A4 [22]. Thus, we have identified the spindle-
shaped interstitial cells immunolocalized by S100-A4 as
fibroblasts. These fibroblasts may arise by the process of
epithelial mesenchymal transition [33, 34]. It has been
suggested that tubular cells may undergo EMT in an
attempt to escape apoptosis, induced possibly by TGF-
b , which is increased in UUO. EMT is accompanied
by a breakdown of the basement membrane, allowing
“escape” of the now spindle-shaped epithelial cells into
the interstitium. In the present study, the number of fi-
broblasts significantly increased in the POK of the 7-day
relief group compared to control. L-arginine treatment
decreased and L-NAME treatment increased the number
of fibroblasts in the POK. NO has been shown to cause
apoptosis in several fibroblastic cell lines, thus increasing
NO may account for the decreased number of fibroblasts.
Alternatively, NO could affect EMT directly. However,
there is a virtual absence of literature on the involvement
of NO in EMT. In an animal model of Peyronie’s disease,
a penile fibrotic disease in which TGF-b is injected into
the tunica albuginea of the penis, there is an activation
of fibroblast to myofibroblasts. Although fibroblast acti-
vation is not the same as EMT, activated fibroblasts have
also has been implicated in UUO and fibrosis. In the Pey-
ronie’s model, inhibition of NOS increased myofibroblast
abundance and collagen synthesis [35]. Thus, the absence
of NO exacerbated fibroblast activation, similar to results
found here using L-NAME.
TGF-b1 has been reported to play an important role
in the cellular and molecular changes characteristic of
UUO. We, and others, have shown increases on TGF-b
in UUO [20, 36]. Although TGF-b1 is increased in the re-
lief model of UUO and presumably involved in tubular
apoptosis, fibroblast expression, and fibrosis, L-arginine
treatment did not alter tissue TGF-b1 levels. This result
was unexpected. In iNOS knockout mice, we have pre-
viously demonstrated an increase in renal TGF-b [14].
Furthermore, several models of fibrosis induced by NOS
inhibition are characterized by increases in TGF-b [37,
38]. Nevertheless, not all studies demonstrate effects of
NO on TGF-b . In 5-day UUO model of rat, L-arginine
treatment did not affect mRNA expression of TGF-b1 in
obstructed kidney [13]. Our in vitro data support this find-
ing. Under stretched condition, NRK-52E, rat kidney ep-
ithelial cells, up-regulated TGF-b production. However,
L-arginine and L-NAME treatment did not affect TGF-b
expression [39]. That NO attenuated renal damage, and
L-NAME exacerbated it, without effects on TGF-b sug-
gests several possibilities. One is that other cytokines, be-
sides TGF-b , are involved. Possible candidates include
angiotensin II or endothelin. A second possibility is that
there were localized effects on TGF-b that were not noted
when we assayed for TGF-b in the whole kidney.
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The obstructed kidney is characterized by both tubular
atrophy and tubular (and interstitial) proliferation. In the
present experiments, the number of PCNA-positive cells
was increased in the POK after relief of UUO. Arginine
treatment decreased tubular proliferation, and L-NAME
blunted its effects. These results are similar to that seen in
iNOS knockout mice, which demonstrated an antiprolif-
erative effect of NO [15]. However, other studies with
renoprotective agents, including TGF-b antibody [20],
anti-inflammatory agent [40], and COX-2 inhibitor [41]
have noted increased tubular proliferation when other
parameters of renal damage are attenuated. There may
be multiple factors involved in both tubular proliferation
and apoptosis whose balance is affected by various treat-
ments, and therefore, divergent effects may be seen.
We also examined the changes in the CK in this model.
For the most part, the CK shows much less damage than
the POK, and was little affected by either L-arginine or L-
NAME. However, TGF-b was increased in the CK in all
groups compared to control kidney. Chevalier et al also
demonstrated prominent renal damage in CK 1 year fol-
lowing relief of UUO and, thus, increased levels of TGF-
b1 in CK might be involved in this process [7]. GFR was
significantly higher in the CK of previously obstructed
rats subjected to 7-day relief compared to control rats.
This demonstrates the compensatory change in the CK
when the other kidney is obstructed. In contrast, GFR in
CK of arginine-treated rats was not significantly different
from control. The lesser change in the CK of arginine-
treated rats might reflect less damage in the POK follow-
ing arginine treatment. Similarly, the CK shows increased
proliferation, which may reflect a compensatory change
in the CK. As in the POK, L-NAME treatment signifi-
cantly decreased ERPF and GFR in CK compared to rats
without L-NAME treatment, suggesting that NO might
be needed for this compensatory change.
CONCLUSION
The recovery of renal function after relief of obstruc-
tion is an important clinical problem. Surgical relief of
obstruction is carried out, and recovery of renal func-
tion is followed as the marker of recovery. However,
pharmacologic agents that affect interstitial fibrosis may
be beneficial adjuncts to this process. There have been
very few studies examining this. When bone morpho-
genetic protein-7 (BMP-7) was administered concomi-
tant with relief of UUO, both GFR and interstitial volume
changes were improved compared to relief alone [42]. In
the present study, we determined that L-arginine admin-
istration decreased tubular apoptosis, macrophage infil-
tration, interstitial fibrosis, and fibroblast expression in
the previously obstructed kidney. In this study, arginine
was administered prior to UUO. In the clinical setting,
any intervention would be done following the diagnosis
or discovery of obstruction. Thus, studies will need to be
carried out in which arginine is administered at the time
of reversal of UUO. Furthermore, long-term follow-up
of reversal needs to be carried out to determine the long-
term effects of reversal on renal function and damage, as
well as to assess the effects of L-arginine on this process.
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